Florida-based biopharmaceutical company Oragenics, Inc. (OTCBB: ORNI) announced its intention to commence a second phase 1 clinical trial of SMaRT Replacement Therapy. The Company has retained PRA International as the Clinical Research Organization (CRO) for clinical trials management services related to the second Phase 1 clinical trial of SMaRT, which is currently set to begin in the first quarter of 2011 at PRA International’s Lenexa, Kansas, clinical facility.
Oragenics’ SMaRT™ Replacement Therapy product candidate is designed to be a painless,
Image via Wikipedia
one time, five-minute topical treatment applied to the teeth that has the potential to offer lifelong protection against dental caries, or tooth decay. SMaRT Replacement Therapy is based on the creation of a genetically modified strain of bacteria that colonizes in the oral cavity and replaces native decay-causing bacteria. This technology was developed by Oragenics’ Chief Scientific Officer, Dr. Jeffrey Hillman, D.M.D., Ph.D. during more than 25 years of research, which began at the Harvard-affiliated Forsyth Institute in Boston and continued at the University of Florida.
PRA International is a global Clinical Research Organization providing services through all phases of clinical development. PRA specializes in oncology, CNS, respiratory/allergy, cardiovascular and infectious diseases. PRA has supported over 2,100 clinical trials in more than 85 countries on 6 continents through its global offices. PRA’s therapeutic expertise, global reach, and project experience with local knowledge enables its project teams to deliver consistent and on time performance for its clients.
PRA International is a global Clinical Research Organization providing services through all phases of clinical development. PRA specializes in oncology, CNS, respiratory/allergy, cardiovascular and infectious diseases. PRA has supported over 2,100 clinical trials in more than 85 countries on 6 continents through its global offices. PRA’s therapeutic expertise, global reach, and project experience with local knowledge enables its project teams to deliver consistent and on time performance for its clients.
Jeffrey D. Hillman
Chief Scientific Officer and Director
Oragenics, Inc.
Sector: HEALTHCARE / Biotechnology
Officer since November 1996
61 Years Old
Dr. Hillman has been our Chief Scientific Officer since November 1996, a Director since November 1996 and served as Chairman of the Board of Directors from November 1996 to December 2004. Since November 1991, Dr. Hillman has been a Professor in the College of Dentistry at the University of Florida in Gainesville, Florida. However, Dr. Hillman retired from the University of Florida, as of July 2008. Dr. Hillman received undergraduate training at the University of Chicago (Phi Beta Kappa), and his D.M.D. degree (cum Laude) from the Harvard School of Dental Medicine and his Ph.D. from Harvard University Medical School. He has authored or co-authored more than 100 publications and textbook chapters on subjects related to infectious diseases, including their etiology and prevention. He has also worked extensively in the area of novel antibiotics. He is the inventor or co-inventor of Oragenics? technologies, including the platform technologies to identify targets for the development of new vaccines and diagnostic tests for a wide variety of infectious diseases and cancer.
